These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17289173)

  • 1. Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: an intravascular ultrasound analysis.
    Hong YJ; Jeong MH; Hwang SH; Yun NS; Lim SY; Lee SR; Hong SN; Kim KH; Park HW; Kim JH; Kim W; Ahn YK; Cho JG; Park JC; Kang JC
    Int J Cardiol; 2007 Dec; 123(1):23-8. PubMed ID: 17289173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial.
    Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Staico R; Feres F; Centemero M; Tanajura LF; Abizaid A; Pinto I; Maldonado G; Seixas A; Costa MA; Paes A; Mintz GS; Sousa JE
    Circulation; 2004 Feb; 109(7):861-6. PubMed ID: 14757690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic abciximab in elective coronary stenting: results of a randomized trial.
    Tamburino C; Russo G; Nicosia A; Galassi AR; Foti R; Scriffignano V; Kereiakes DJ; Giuffrida G
    J Invasive Cardiol; 2002 Feb; 14(2):72-9. PubMed ID: 11818641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial.
    Sonoda S; Morino Y; Ako J; Terashima M; Hassan AH; Bonneau HN; Leon MB; Moses JW; Yock PG; Honda Y; Kuntz RE; Fitzgerald PJ;
    J Am Coll Cardiol; 2004 Jun; 43(11):1959-63. PubMed ID: 15172398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
    Kim SS; Hong YJ; Jeong MH; Kim W; Kim HK; Ko JS; Lee MG; Sim DS; Park KH; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Song SJ; Cho DL; Kang JC
    Circ J; 2010 Mar; 74(3):442-8. PubMed ID: 20103970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction.
    Kim W; Jeong MH; Kim KH; Sohn IS; Hong YJ; Park HW; Kim JH; Ahn YK; Cho JG; Park JC; Cho DL; Kang JC
    J Am Coll Cardiol; 2006 Mar; 47(5):933-8. PubMed ID: 16516074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular response to sirolimus-eluting stents delivered with a nonaggressive implantation technique: comparison of intravascular ultrasound results from the multicenter, randomized E-SIRIUS, and SIRIUS trials.
    Hoffmann R; Guagliumi G; Musumeci G; Reimers B; Petronio AS; Disco C; Amoroso G; Moses JW; Fitzgerald PJ; Schofer J; Leon MB; Breithardt G
    Catheter Cardiovasc Interv; 2005 Dec; 66(4):499-506. PubMed ID: 16273564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials.
    Hoffmann R; Morice MC; Moses JW; Fitzgerald PJ; Mauri L; Breithardt G; Schofer J; Serruys PW; Stoll HP; Leon MB
    Heart; 2008 Mar; 94(3):322-8. PubMed ID: 17761505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study.
    De Luca L; Sardella G; De Persio G; Petrolini A; Fedele F
    Acute Card Care; 2008; 10(2):93-9. PubMed ID: 18568571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome after acute incomplete sirolimus-eluting stent apposition as assessed by serial intravascular ultrasound.
    Kimura M; Mintz GS; Carlier S; Takebayashi H; Fujii K; Sano K; Yasuda T; Costa RA; Costa JR; Quen J; Tanaka K; Lui J; Weisz G; Moussa I; Dangas G; Mehran R; Lansky AJ; Kreps EM; Collins M; Stone GW; Moses JW; Leon MB
    Am J Cardiol; 2006 Aug; 98(4):436-42. PubMed ID: 16893693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of IVUS guided bare metal stent implantation for non-small vessel.
    Kataoka T; Shimada K; Fukuda D; Nishioka H; Oda S; Ehara S; Hirose M; Kamimori K; Kobayashi Y; Yoshiyama M; Takeuchi K; Yoshikawa J
    Osaka City Med J; 2004 Dec; 50(2):79-86. PubMed ID: 15819302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials).
    Tsuchiya Y; Lansky AJ; Costa RA; Mehran R; Pietras C; Shimada Y; Sonoda S; Cristea E; Negoita M; Dangas GD; Moses JW; Leon MB; Fitzgerald PJ; Müller R; Störger H; Hauptmann KE; Grube E
    Am J Cardiol; 2006 Aug; 98(4):464-9. PubMed ID: 16893698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries.
    Hong YJ; Jeong MH; Kim W; Lim SY; Lee SH; Hong SN; Kim JH; Ahn YK; Cho JG; Park JC; Cho DL; Kim H; Kang JC
    Am J Cardiol; 2004 Oct; 94(8):1050-4. PubMed ID: 15476624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trials.
    Doi H; Maehara A; Mintz GS; Weissman NJ; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Stone GW
    Circ Cardiovasc Interv; 2008 Oct; 1(2):111-8. PubMed ID: 20031665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of late incomplete stent apposition: a comparison among bare-metal stents, intracoronary radiation and sirolimus-eluting stents.
    Miyazawa A; Tsujino I; Ako J; Shimada Y; Courtney BK; Sakurai R; Nakamura M; Okura H; Waseda K; Honda Y; Fitzgerald PJ
    J Invasive Cardiol; 2007 Dec; 19(12):515-8. PubMed ID: 18180522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of edge stenosis following sirolimus-eluting stent deployment (a quantitative intravascular ultrasound analysis from the SIRIUS trial).
    Sakurai R; Ako J; Morino Y; Sonoda S; Kaneda H; Terashima M; Hassan AH; Leon MB; Moses JW; Popma JJ; Bonneau HN; Yock PG; Fitzgerald PJ; Honda Y;
    Am J Cardiol; 2005 Nov; 96(9):1251-3. PubMed ID: 16253592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up.
    Degertekin M; Serruys PW; Foley DP; Tanabe K; Regar E; Vos J; Smits PC; van der Giessen WJ; van den Brand M; de Feyter P; Popma JJ
    Circulation; 2002 Sep; 106(13):1610-3. PubMed ID: 12270850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of late-acquired incomplete stent apposition after drug-eluting stent versus bare-metal stent. A meta-analysis from 12 randomized trials.
    Sanchez-Recalde A; Moreno R; Barreales L; Rivero F; Galeote G; Jimenez-Valero S; Calvo L; López de Sá E; López-Sendón JL
    J Invasive Cardiol; 2008 Aug; 20(8):417-22. PubMed ID: 18688067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial.
    Tanabe K; Serruys PW; Degertekin M; Grube E; Guagliumi G; Urbaszek W; Bonnier J; Lablanche JM; Siminiak T; Nordrehaug J; Figulla H; Drzewiecki J; Banning A; Hauptmann K; Dudek D; Bruining N; Hamers R; Hoye A; Ligthart JM; Disco C; Koglin J; Russell ME; Colombo A;
    Circulation; 2005 Feb; 111(7):900-5. PubMed ID: 15710761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.